KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCvaccines Revenue BreakdownDeferred RevenueEbt By SegmentEbt Margin By Segment %Employee StatisticsGross Margin %Gross ProfitGross Profit AnnualGross Profit Annual %Hospital Revenue BreakdownIncome Before Income TaxInflammation And Immunology Revenue BreakdownInternal Medicine Revenue BreakdownInventoriesLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue BreakdownOperating Costs & ExpensesOpex & Costs As A % Of RevenueProperty, Plant And Equipment SegregationRare Disease Revenue BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical Annual %Revenue By Customer GroupRevenue By Customer Group %Revenue By Products AnnualaRevenue By Products Annuala %Revenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Therapeutic Area AnnualRevenue By Therapeutic Area Annual %Revenue By WholesalersRevenue By Wholesalers %U.S Revenue By Wholesalers %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Gross Profit (2016 - 2025)

Pfizer (PFE) has disclosed Gross Profit for 17 consecutive years, with $26.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 161.41% to $26.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $46.5 billion, a 222.6% increase, with the full-year FY2025 number at $46.5 billion, up 591.51% from a year prior.
  • Gross Profit was $26.6 billion for Q4 2025 at Pfizer, up from -$1.9 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $26.6 billion in Q4 2025 to a low of -$43.4 billion in Q4 2024.
  • A 5-year average of $5.3 billion and a median of $10.6 billion in 2021 define the central range for Gross Profit.
  • Biggest YoY gain for Gross Profit was 1013.42% in 2024; the steepest drop was 950.99% in 2024.
  • Pfizer's Gross Profit stood at $14.2 billion in 2021, then increased by 17.04% to $16.6 billion in 2022, then crashed by 124.9% to -$4.1 billion in 2023, then plummeted by 950.99% to -$43.4 billion in 2024, then soared by 161.41% to $26.6 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Gross Profit are $26.6 billion (Q4 2025), -$1.9 billion (Q3 2025), and $10.9 billion (Q2 2025).